Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

被引：0
|
作者：
Antonio Daponte
Simona Signoriello
Luigi Maiorino
Bruno Massidda
Ester Simeone
Antonio Maria Grimaldi
Corrado Caracò
Giuseppe Palmieri
Antonio Cossu
Gerardo Botti
Antonella Petrillo
Secondo Lastoria
Ernesta Cavalcanti
Pasquale Aprea
Nicola Mozzillo
Ciro Gallo
Giuseppe Comella
Paolo Antonio Ascierto
机构：
[1] Istituto Nazionale Tumori Fondazione Pascale,Department of Melanoma
[2] Second University,Medical Statistics
[3] S.Gennaro Hospital Napoli,Medical Oncology
[4] University of Cagliari,Medical Oncology
[5] Institute of Biomolecular Chemistry,Unit of Cancer Genetics
[6] C.N.R.,Department of Pathology
[7] Azienda Ospedaliero Universitaria,Department of Pathology
[8] Istituto Nazionale Tumori Fondazione Pascale,Department of Radiology
[9] Istituto Nazionale Tumori Fondazione Pascale,Department of Nuclear Medicine
[10] Istituto Nazionale Tumori Fondazione Pascale,Laboratory Medicine Unit
[11] Istituto Nazionale Tumori Fondazione Pascale,Vascular Access Unit
[12] Istituto Nazionale Tumori Fondazione Pascale,undefined
[13] the Southern Italy Cooperative Oncology Group (SICOG),undefined
来源：
Journal of Translational Medicine | / 11卷
关键词：
Melanoma; Fotemustine; Dacarbazine; Interferon-α;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
    Daponte, Antonio
    Signoriello, Simona
    Maiorino, Luigi
    Massidda, Bruno
    Simeone, Ester
    Grimaldi, Antonio Maria
    Caraco, Corrado
    Palmieri, Giuseppe
    Cossu, Antonio
    Botti, Gerardo
    Petrillo, Antonella
    Lastoria, Secondo
    Cavalcanti, Ernesta
    Aprea, Pasquale
    Mozzillo, Nicola
    Gallo, Ciro
    Comella, Giuseppe
    Ascierto, Paolo Antonio
    JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11
  • [2] A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
    Middleton M.R.
    Lorigan P.
    Owen J.
    Ashcroft L.
    Lee S.M.
    Harper P.
    Thatcher N.
    British Journal of Cancer, 2000, 82 (6) : 1158 - 1162
  • [3] Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study
    Avril, MF
    Aamdal, S
    Grob, JJ
    Hauschild, A
    Mohr, P
    Bonerandi, JJ
    Weichenthal, M
    Neuber, K
    Bieber, T
    Gilde, K
    Porta, VG
    Fra, J
    Bonneterre, J
    Saïag, P
    Kamanabrou, D
    Pehamberger, H
    Sufliarsky, J
    Larriba, JLG
    Scherrer, A
    Menu, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) : 1118 - 1125
  • [4] Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
    Middleton, MR
    Grob, JJ
    Aaronson, N
    Fierlbeck, G
    Tilgen, W
    Seiter, S
    Gore, M
    Aamdal, S
    Cebon, J
    Coates, A
    Dreno, B
    Henz, M
    Schadendorf, D
    Kapp, A
    Weiss, J
    Fraass, U
    Statkevich, P
    Muller, M
    Thatcher, N
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) : 158 - 166
  • [5] Fotemustine (FM) and dacarbazine (DTIC) versus DTIC ± interferon α in advanced malignant melanoma:: A phase III study of the Southern Italy Cooperative Oncology Group (SICOG)
    Comella, G.
    Maiorino, L.
    Filippelli, G.
    Massidda, B.
    Mozzillo, N.
    Caraco, C.
    Ascierto, P. A.
    Chiofalo, M. G.
    Simeone, E.
    Daponte, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 936S - 936S
  • [6] FOTEMUSTINE WITH OR WITHOUT DACARBAZINE FOR BRAIN METASTASES OF MALIGNANT-MELANOMA
    MERIMSKY, O
    INBAR, M
    REIDERGROSWASSER, I
    CHAITCHIK, S
    EUROPEAN JOURNAL OF CANCER, 1991, 27 (08) : 1066 - 1066
  • [7] Cisplatin, dacarbazine, fotemustine, and interferon-α2B in advanced melanoma:: A phase II study of Italian Melanoma Study Group (IMSG)
    Daponte, A
    Comella, P
    Cellerino, R
    De Lena, M
    Brandi, M
    Marini, G
    Failla, G
    De Vita, F
    Rivellini, F
    Gravina, A
    Mozzillo, N
    Caraco, C
    Comella, G
    ANNALS OF ONCOLOGY, 1998, 9 : 117 - 117
  • [8] DACARBAZINE VERSUS DACARBAZINE VINDESINE IN DISSEMINATED MALIGNANT-MELANOMA - A RANDOMIZED PHASE-II STUDY
    RINGBORG, U
    RUDENSTAM, CM
    HANSSON, J
    HAFSTROM, L
    STENSTAM, B
    STRANDER, H
    MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY, 1989, 6 (04): : 285 - 289
  • [9] Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma:: An Eastern Cooperative Oncology Group study
    Falkson, CI
    Ibrahim, J
    Kirkwood, JM
    Coates, AS
    Atkins, MB
    Blum, RH
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) : 1743 - 1751
  • [10] FOTEMUSTINE PLUS DACARBAZINE FOR MALIGNANT-MELANOMA
    AVRIL, MF
    BONNETERRE, J
    CUPISSOL, D
    GROB, JJ
    KALIS, B
    FUMOLEAU, P
    KERBRAT, P
    ISRAEL, L
    FARGEOT, P
    LAMBERT, D
    DELAUNAY, M
    DRENO, B
    VILMER, C
    BIZZARI, JP
    COUR, V
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (11) : 1807 - 1811
12345